Topical β‐blockers for pyogenic granulomas: A promising option for younger patients.

Background: Topical β‐blockers, propranolol, and timolol were used for pyogenic granuloma (PG) treatment; however, their efficacies and safety profiles were not compared. Aims: The aim was to evaluate the safety and efficacy of propranolol 1% and timolol 0.5% creams in the treatment of pyogenic granulomas. Patients: The study included 30 PG patients. They were divided into three groups (10 patients each). Group I patients received propranolol 1% cream. Group II patients used timolol 0.5% l cream. Group III patients used placebo cream. Creams were applied twice daily for 2 months. Patients were followed up for 3 months to detect any recurrence. Results: Complete resolution was reported in 6 patients of groups I and II, while none of the control patients reported complete resolution. Despite the absent change in lesions' size in 40% of β‐blockers treated groups, they all reported decreased bleeding tendency. There was insignificant difference between the clinical responses between β‐blockers groups. No recurrence was reported in any of the patients who achieved complete resolution after 3 months of follow‐up. Younger patients respond better to β‐blockers. Three patients were deteriorated on beta‐blockers treatment. Conclusion: β‐blockers are a promising PG treatment option in cases where invasive modalities are not desirable especially in younger patients. [ABSTRACT FROM AUTHOR]